Nobivac Pi vet.

10 x 1 dose

Lyophilisate and solvent for suspension for injection

Active substance

Canine parainfluenza virus (CPIV) (Strain Cornell) (attenuated)

ATC code

QI07AD08 Canine parainfluenza virus (CPIV)

QI07AD Live viral vaccines

QI07A Immunologicals for dog

QI07 Immunologicals for canidae

QI Immunologicals

Species

Dogs.

Indications

For active immunisation of dogs from the age of 8 weeks onwards to reduce clinical signs of canine para-influenza infection and to reduce viral shedding.

Onset of immunity: 4 weeks after vaccination.

Duration of immunity: has not been demonstrated, but an anamnestic response is produced in dogs given a revaccination 1 year after basic vaccination.

Dose to be administered and administration route

One ml solvent or 1 ml (1 dose) of inactivated vaccine (as specified in section 3.8) must be used to reconstitute this freeze-dried vaccine.

One dose (1 ml) of reconstituted vaccine should be given by subcutaneous injection. Sterile equipment should be used for administration.

Vaccination schedule:

- Basic vaccination:

Before the age of 12 weeks:

Two vaccinations, each with a single dose: the first vaccination from the age of 8 weeks onwards and the second vaccination 2 - 4 weeks later.

From the age of 12 weeks onwards:

Single vaccination, with one dose per animal.

- Revaccination:

Every year with a single dose.

Reconstituted product: off-pink or pink suspension.

Adverse reactions

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Discomfort^¹.

Injection site swelling^².

Hypersensitivity reaction^³.

¹During injection.

²Diffuse up to 5 mm in diameter , which may occasionally be hard and painful and last up to 3 days post injection.

³ In the event of an anaphylactic reaction, appropriate treatment such as adrenaline should be administered without delay.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.